Lantern Pharma Inc - Asset Resilience Ratio
Lantern Pharma Inc (LTRN) has an Asset Resilience Ratio of 29.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Lantern Pharma Inc (LTRN) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Lantern Pharma Inc's Asset Resilience Ratio has changed over time. See LTRN book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Lantern Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Lantern Pharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.97 Million | 29.16% |
| Total Liquid Assets | $3.97 Million | 29.16% |
Asset Resilience Insights
- Very High Liquidity: Lantern Pharma Inc maintains exceptional liquid asset reserves at 29.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Lantern Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Lantern Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Lantern Pharma Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Lantern Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 64.53% | $16.50 Million | $25.57 Million | +20.17pp |
| 2023-12-31 | 44.37% | $19.36 Million | $43.65 Million | +13.78pp |
| 2022-12-31 | 30.58% | $17.99 Million | $58.84 Million | +4.62pp |
| 2021-12-31 | 25.96% | $19.20 Million | $73.95 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $20.36 Million | -- |
About Lantern Pharma Inc
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as gliob… Read more